Generics, pharma firms’ tie-up launches new asthma drug


rHEA Generics, a homegrown pioneer in the marketing and distributi­on of high quality and affordable health-care products, has entered a new partnershi­p with leading pharmaceut­ical company boehringer Ingelheim (Philippine­s), Inc. (BIPHI). The initial offering from this partnershi­p is the launch of an affordable combinatio­n medication for the management of reversible bronchospa­sm associated with obstructiv­e airway diseases that include chronic obstructiv­e pulmonary disease (COPD) and asthma.

both asthma and COPD fall under respirator­y diseases, a group of illnesses consistent­ly ranked among the top causes of death in the Philippine­s. As of 2018, the morbidity rate of respirator­y illnesses in the Philippine­s was approximat­ely 1.1 thousand per 100,000 people.

Asthma refers to a medical condition in which the body’s airways narrow and swells, triggering breathing difficulti­es. It can be a very serious medical condition. The Philippine­s ranks 9th globally in terms of asthma mortality. On the other hand, COPD refers to a group of diseases that cause airflow blockage and breathing-related problems. Locally, COPD is among the top 10 causes of death in the country. with known causes including tobacco smoke, air pollutants, and other respirator­y infections, the effects of COPD can range from activity limitation­s to the onset of other chronic diseases such as arthritis or diabetes.

Financial burden

WHILE treatable, a patient may experience additional financial burden with medication, pulmonary rehabilita­tion, supplement­al oxygen, and other measures to manage asthma and COPD. Through the partnershi­p with BIPHI, the medication offered by RHEA Generics will be sold at a price of up to 44% more affordable than other brands in the market.

“we are beyond excited to establish a partnershi­p with boehringer Ingelheim [Philippine­s], Inc. to further bolster efforts in providing every Filipino family with access to world-class quality medicines at the most affordable cost,” said Neogin evangelist­a, president and general manager of Philusa Corporatio­n.

Asked about the first product released through the partnershi­p, evangelist­a added, “BIPHI has been instrument­al in the creation of the RHEA Generics medication for the treatment of asthma and chronic obstructiv­e pulmonary disease. As a result, we will now be offering a product with a lower price compared to competitor­s while delivering the same level of quality, efficacy, and safety as the innovator brand.”

“Value through innovation has always been the guiding principle at boehringer Ingelheim [Philippine­s], Inc. In today’s competitiv­e and fastchangi­ng world, our commitment to the research, developmen­t, and production of quality medicine must coincide with the drive to ensure greater access to our innovation­s. This partnershi­p with RHEA Generics is symbolic of a vision both companies share— improving the quality of life for as many people as possible,” said yee Kok Cheong, general manager, boehringer Ingelheim (Philippine­s),inc.

This new RHEA Generics medicine will be available in all Mercury Drug stores starting this July 2021.

Newspapers in English

Newspapers from Philippines